US Residents Only

Patient Site

CHANGE THE DELIVERY, IMPROVE THE RESULTS

Simple

Effective

Efficent

Breakfast

Lunch

Snack

Dinner

24 hour

V-Go® is an all-in-one insulin delivery patch that delivers a continuous preset basal rate of insulin and provides on-demand bolus dosing.1
Clinically proven to reduce A1C with less insulin.2-10

See How V-Go Works

V-Go is designed to simplify insulin delivery by combining basal and bolus coverage in one insulin delivery patch to improve results.

V-Go

  • Eliminates the need for basal and bolus injections1-10
  • Requires only 1 type of insulin (U-100 rapid
    acting insulin)1
  • Takes less than a minute to fill1
  • Applied without an inserter once a day and worn for
    24 hours1
  • Delivers insulin without programming or controllers1
  • Improves glycemic control2-9

V-Go is Proven Effective and Efficient Across
Adult Patients with Diabetes Requiring Insulin2-10

V-Go Clinical Benefits

Improved Blood Glucose:

Switching to V-Go from prior glucose lowering therapies reduced mean A1C by 1.8% at 6 months2

Decreased Insulin:

Switching to V-Go from prior therapies including prescribed insulin decreased mean prescribed insulin by 36%2
Data from a restrospective study in 153 patients with diabetes with a mean A1C of 9.7% before switching to V-Go. Prior therapies included a prescription of at least one of the following: basal insulin, bolus insulin, GLP-1 RA, or oral glucose lowering medication.2

WHO IS V-GO FOR?

Adult Patients Requiring Insulin

Commonly Prescribed in Patients

Not achieving glucose targets

Consistently missing insulin injections

Struggling with the complexities of MDI

Fearful of injection pain

Achieving glucose targets but the patient would prefer to take fewer insulin injections

Learn More

See How V-Go Can Benefit Patients in this Quick Video Overview

Watch the Video

References: 1. Instructions for Patient Use. DCN 2560 Rev.C 06.22. 2. Lajara R, Nikkel C. Poster Presented at ACCE. May 2015. 3. Sutton D, Higdon C, Nikkel C, Hilsinger K. Advances in Therapy. May 2018. 4. Lajara R, Fetchick DA, Morris TL, Nikkel CN. Diabetes Ther. Oct 2015. 5. Everitt B, Harrison HC Jr, Nikkel C, Laswell E, Chen AMH. Sept 2019. 6. Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Drugs Real World Outcomes. Mar 2020. 7. Hundal R, Kowalyk S, Wakim A, Nikkel C, Sink Ii JH, Doyle M. Sep 2020. 8. Zeidan T, Nikkel C, Dziengelewski B, Wu S, Chen AMH. Pharmacy. Nov 2020. 9. Rosenfeld CR, Bohannon NJ, Bode B, Kelman AS, Mintz SN, Schorr AB, Sandberg MI, Nambi S, Agarwala SK, Leichter SB, Larrabee B, Shi L, Strange P. Sept Endocr Pract. 2012. 10. Lajara R, Davidson JA, Nikkel CC, Morris TL. Endocr Pract Jun 2016.

US-VGO-0109